Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:56:34 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - https://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  2506.00.01·0.015209.00.01532.1080.015  0.015  0.0150.045  0.0115:04:50Jun 2515 min RT 2¢
TSX - T2506.00.01·0.015209.00.01517.0030.015  0.015  0.0150.045  0.0115:04:5015 min
Pure - P 0.01514.0010.015  0.015  0.01510:48:2115 min
CXD - D 0.0150.0011    Apr 0415 min
TriAct - M 0.0151.13    Sep 11/2015 min

Recent Trades - All 8 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:04:50T0.015 5,00080 National Bank84 ITG84K
11:36:02M0.015 1080 National Bank7 TD SecE
10:48:21M0.015 6661 Anonymous7 TD SecE
10:48:21P0.015 14,0002 RBC1 AnonymousK
09:59:10M0.015 44880 National Bank80 National BankE
09:30:01D0.01-0.005180 National Bank80 National BankE
09:30:00T0.015 7,00019 Desjardins84 ITG84KL
09:30:00T0.015 5,00019 Desjardins2 RBCKL
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-06-25 20:49C:APLI0.015SEDAR Annual Information FormSEDAR Annual Information Form
2025-06-25 20:39C:APLI0.015SEDAR MD & ASEDAR MD & A
2025-06-25 20:26C:APLI0.015SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-06-25 18:04C:APLI0.015News ReleaseAppili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
2025-05-30 16:19C:APLI0.015News ReleaseAppili terminates arrangement with Aditxt
2025-05-20 02:24C:APLI0.03News ReleaseAppili to receive termination fee from Aditxt
2025-05-01 07:34C:APLI0.03News ReleaseAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
2025-04-28 17:47C:APLI0.03News ReleaseAppili Therapeutics granted patents in U.S., Mexico
2025-04-02 17:23C:APLI0.03News ReleaseAppili president to join Aditxt's April 4 update
2025-03-18 17:35C:APLI0.035News ReleaseAppili Therapeutics submits U.S. funding applications
2025-02-14 17:59C:APLI0.03SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-14 17:53C:APLI0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-14 17:06C:APLI0.03News ReleaseAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
2024-12-12 08:15C:APLI0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLI0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLI0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLI0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLI0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLI0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders